Anti-U11/U12 Antibodies as a Rare but Important Biomarker in Patients with Systemic Sclerosis : A Narrative Review
Fritzler, Marvin J. (University of Calgary)
Bentow, Chelsea (Werfen)
Beretta, Lorenzo (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milan)
Palterer, Boaz (University of Florence)
Perurena-Prieto, Janire (Hospital Universitari Vall d'Hebron)
Sanz-Martínez, María Teresa (Hospital Universitari Vall d'Hebron)
Guillén-Del-Castillo, Alfredo (Hospital Universitari Vall d'Hebron)
Marín-Sánchez, Ana (Hospital Universitari Vall d'Hebron)
Fonollosa Pla, Vicent (Hospital Universitari Vall d'Hebron)
Callejas Moraga, Eduardo Luis (Hospital Público de Monforte)
Simeón-Aznar, Carmen Pilar (Hospital Universitari Vall d'Hebron)
Mahler, Michael (Werfen)
Universitat Autònoma de Barcelona

Data:	2023
Resum:	Anti-nuclear (ANA) are present in approximately 90% of systemic sclerosis (SSc) patients and are key biomarkers in supporting the diagnosis and determining the prognosis of this disease. In addition to the classification criteria autoantibodies for SSc [i. e. , anti-centromere, anti-topoisomerase I (Scl-70), anti-RNA polymerase III], other autoantibodies have been associated with important SSc phenotypes. Among them, anti-U11/U12 ribonucleoprotein (RNP) antibodies, also known as anti-RNPC-3, were first reported in a patient with SSc, but very little is known about their association and clinical utility. The U11/U12 RNP macromolecular complex consists of several proteins involved in alternative mRNA splicing. More recent studies demonstrated associations of anti-anti-U11/U12 antibodies with SSc and severe pulmonary fibrosis as well as with moderate to severe gastrointestinal dysmotility. Lastly, anti-U11/U12 autoantibodies have been strongly associated with malignancy in SSc patients. Here, we aimed to summarize the knowledge of anti-U11/U12/RNPC-3 antibodies in SSc, including their seroclinical associations in a narrative literature review.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Autoantibodies ; Interstitial lung disease ; SSc ; Systemic sclerosis ; U11/U12
Publicat a:	Diagnostics, Vol. 13 (march 2023) , ISSN 2075-4418

DOI: 10.3390/diagnostics13071257
PMID: 37046475

13 p, 1.3 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats